# Sobi (Swedish Orphan Biovitrum)

**Canonical:** https://apis.io/providers/sobi/  
**Website:** https://www.sobi.com/  
**APIs profiled:** 0

Sobi (Swedish Orphan Biovitrum) is a global biopharmaceutical company focused on developing innovative medicines for rare diseases. The company aims to transform the lives of patients with rare and ultra‑rare conditions through a robust pipeline of therapies, extensive research, and collaborations worldwide. Sobi operates from its headquarters in Stockholm, Sweden, and maintains a presence across Europe and the United States, delivering treatments in hematology, immunology, and neurology.

## Kin Score — 5.1 / 100 (minimal)

Scored 2026-11-06 under rubric 0.27.0. Trend: flat (-1.4 from 6.5).

| Facet | Score |
|---|---|
| Discoverability | 49.1 |
| Contract Quality | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Access Clarity | 5.3 |

Regulatory layer — **Health**: 6.3 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |
| Delegated Identity | no |
| Protected Resource Metadata | no |
| Dynamic Client Registration | no |
| Agentic Commerce | no |
| Pagination Ratio | na |
| Operation Distinctiveness | na |
| MCP Tool Quality | na |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Sobi Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biopharma, Rare Disease, Sweden, Healthcare

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/sobi/). Scores are computed from the provider's own public artifacts under a published rubric.